Ebpay生命医药出版社

Ebpay生命

100763

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

济威二珍丸顺利获得调节 SIRT1/JNK/p38 MAPK 通路改善雄激素性脱发

 

Authors Huang Z, Li Y, Xie Y, Fu H, Weng Z, Yuan J, Wu L, Lin W, Cao Y, Ding B 

Received 5 November 2024

Accepted for publication 26 March 2025

Published 1 April 2025 Volume 2025:19 Pages 2393—2409

DOI http://doi.org/10.2147/DDDT.S501823

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Tin Wui Wong

Zhiguang Huang,1,2,* Yuanyuan Li,3,* Yixin Xie,1,2,* Hangjie Fu,2,4 Zhiwei Weng,1,2 Jianchang Yuan,1,2 Lan Wu,1,2 Weizhou Lin,1,2 Yi Cao,3 Bin Ding1,2,5 

1School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 2Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 3The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 4School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 5Jiaxing TCM Hospital Affiliated to Zhejiang Chinese Medical University, Jiaxing, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Bin Ding, College of Life Science, Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou, 310053, People’s Republic of China, Tel +86 18058107528, Email db@zcmu.edu.cn Yi Cao, The First Affiliated Hospital of Zhejiang Chinese Medical University, 289 Shanggang Road, Xihu District, Hangzhou, 310060, People’s Republic of China, Email caoyi1965@163.com

Purpose: Androgenetic alopecia (AGA) is a type of hair loss. Our previous study showed AGA ameliorating capability of water extract of an herbal prescription, “Jiawei Erzhiwan” (WJWE), which was derived from the traditional formula “Erzhiwan”. However, the underlying mechanisms is still unknown.
Patients and Methods: In this study, the phytochemical ingredients in WJWE were characterized via UPLC‒MS/MS analysis. The dihydrotestosterone (DHT)-induced murine model and dermal papilla cells (DPCs) assays were used to evaluate and elucidate the beneficial effects and mechanisms of WJWE on AGA.
Results: WJWE promoted hair growth and hair follicle regeneration in AGA mice, improved DPCs growth and dose-dependently protected DHT-reduced DPCs viability in vitro by stimulating the Wnt5A/β-Catenin pathway. Additionally, WJWE reduced DHT-induced oxidative stress in AGA model murine skin and DHT-treated DPCs. To elucidate the regulative mechanism, we found that WJWE treatment significantly and dose-dependently increased the expression of SIRT1 and reduced the phosphorylation of JNK and p38 MAPK in both DHT-treated DPCs and AGA model mice. And the application of EX527 (a SIRT1 inhibitor) could the effect of WJWE.
Conclusion: Our study provided some evidence of WJWE on AGA treatment, by which SIRT1/JNK/p38 MAPK signaling pathway might be the major target.

Keywords: androgenetic alopecia, Erzhiwan, JNK, p38 MAPK, oxidative stress, SIRT1

Download Article[PDF]